<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="c83ced5f-9bf2-4367-9146-5b17d0b83371"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Pentamidine Isethionate for injection</title>
   <effectiveTime value="20250402"/>
   <setId root="cb8e8155-5505-44d5-9dee-525e2e45b95d"/>
   <versionNumber value="8"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="828898002" root="1.3.6.1.4.1.519.1"/>
            <name>Seton Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="828898002"/>
                  <name>Seton Pharmaceuticals</name>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="454548bf-19cf-474a-a3b6-04c5bde92a8f"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL LISTING DATA ELEMENTS SECTION"/>
               <effectiveTime value="20180320"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="13925-515" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Pentamidine Isethionate </name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pentamidine Isethionate </name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator unit="mg" value="300"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="V2P3K60DA2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PENTAMIDINE ISETHIONATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="673LC5J4LQ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PENTAMIDINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mg" value="300"/>
                              <denominator value="1.0"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1.0"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="13925-515-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180401"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA206666" root="2.16.840.1.113883.3.150"/>
                           <code displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1" code="C73584"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180401"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="08601c34-cee2-4ae6-8d9f-75d170697357"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">For Injection Only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="55770f54-c995-403f-b5fc-1e44102dfefd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Pentamidine isethionate for injection, an anti-protozoal agent, is a sterile, nonpyrogenic, lyophilized product.  After reconstitution, it should be administered by intramuscular (IM) or intravenous (IV) routes (see <content styleCode="bold">
                        <linkHtml href="#s12">DOSAGE AND ADMINISTRATION</linkHtml>
                     </content>).  Pentamidine isethionate is a white crystalline powder soluble in water and glycerin, slightly soluble in alcohol and insoluble in ether, acetone, and chloroform.  It is chemically designated as 4,4-[1,5-pentanediylbis(oxy)]bis-benzenecarboximidamid with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm01"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Each vial contains:</content>
                     <br/>Pentamidine isethionate . . . . . . . . . . . . . 300 mg</paragraph>
               </text>
               <effectiveTime value="20190501"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>pentam-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cb8e8155-5505-44d5-9dee-525e2e45b95d-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="d1722f24-94e2-49cf-833c-a2c0badd767c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Pentamidine isethionate, an aromatic diamidine, is known to have activity against <content styleCode="italics">Pneumocystis carinii</content>.  The mode of action of pentamidine is not fully understood.  <content styleCode="italics">In vitro</content> studies indicate that the drug interferes with protozoal nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis.</paragraph>
               </text>
               <effectiveTime value="20190501"/>
               <component>
                  <section ID="s3">
                     <id root="c547b022-8fe7-4ffe-a96e-9b84374a589f"/>
                     <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>Pharmacokinetic parameters following the administration of 4 mg/kg pentamidine isethionate as a single two-hour intravenous infusion or after a single intramuscular injection to 12 patients with AIDS are presented in the following table: </paragraph>
                        <table width="100%">
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" rowspan="2" valign="middle">
                                    <paragraph>Mean ±</paragraph>
                                    <paragraph>SD</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" rowspan="2" align="center" valign="middle">
                                    <paragraph>C<sub>max</sub>
                                    </paragraph>
                                    <paragraph>ng/mL</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" rowspan="2" align="center" valign="middle">
                                    <paragraph>Clearance</paragraph>
                                    <paragraph>L/h</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" rowspan="2" align="center" valign="middle">
                                    <paragraph>Half-life</paragraph>
                                    <paragraph>hours</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" rowspan="2" align="center" valign="middle">
                                    <paragraph>Vdss</paragraph>
                                    <paragraph>L</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" colspan="2" align="center" valign="middle">
                                    <paragraph>Concentration</paragraph>
                                    <paragraph>ng/mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top" align="center">
                                    <paragraph>8 hour</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>24 hour</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>2 hour I.V. infusion </paragraph>
                                    <paragraph>4 mg/kg (N=6)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>612 ± 371</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>248 ± 91</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>6.4 ± 1.3</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>821 ± 535</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>19.3 ± 16.9</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>2.9 ± 1.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>I.M. </paragraph>
                                    <paragraph>4 mg/kg (N=6)</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>209 ± 48</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>305 ± 81</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>9.4 ± 2.0</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>2724 ± 1066</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>22.9 ± 8.0</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>6.6 ± 3.5</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In seven patients treated with daily IM doses of pentamidine at 4 mg/kg for 10 to 12 days, plasma concentrations were between 300 to 500 ng/mL.  The concentrations did not appreciably change with time after injection or from day to day.  Higher plasma concentrations were encountered in patients with an elevated blood urea nitrogen.  The patients continued to excrete decreasing amounts of pentamidine in urine up to 6 to 8 weeks after cessation of the treatment.</paragraph>
                        <paragraph>Following multiple intravenous administration of pentamidine isethionate (3.7 to 4 mg/kg/day infused over 4 hours) to 6 patients with AIDS being treated for PCP, the pharmacokinetic parameters obtained on Days 1,4 and 7 are summarized in the following table:</paragraph>
                        <table width="100%">
                           <tbody>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>Mean</paragraph>
                                    <paragraph> ± SD</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>C<sub>max</sub>
                                       <footnote ID="FN1">derived from Lidman</footnote>
                                    </paragraph>
                                    <paragraph>ng/mL</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>C<sub>min</sub>
                                       <footnoteRef IDREF="FN1"/>
                                    </paragraph>
                                    <paragraph>ng/mL</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>Clearance</paragraph>
                                    <paragraph>mL/min</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>Renal Clearance mL/min/1.73 m<sup>2</sup>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>Creatinine Clearance mL/min/1.73 m<sup>2</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>Day 1</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>175.3 ± 54</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>---</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>5737 ± 1878</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>269 ± 149</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>97 ± 12</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>Day 4</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>210.9 ± 80</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>17.6 ± 9.5</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>3350 ± 1944</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>214 ± 145</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>93 ± 17</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                                    <paragraph>Day 7</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>256.7 ± 89</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>40.8 ± 16.1</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>1989 ± 566</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>134 ± 60</paragraph>
                                 </td>
                                 <td styleCode="Lrule Rrule Toprule Botrule" align="center" valign="middle">
                                    <paragraph>69 ± 17</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Compared to the mean AUC on Day 1, AUC on Day 4 and Day 7 were about 2 and 3 fold higher, respectively, suggesting that steady state was not achieved by Day 7 of dosing.</paragraph>
                        <paragraph>In other published reports of pharmacokinetics of pentamidine following daily intravenous doses of 2 to 4 mg/kg/day, clearance ranged from 30 to 40 mL/min/kg and Vdss ranged from 200 to 400 L/kg.  Reported values for terminal half-lives of 2.8 to 12 days is suggestive of a deep peripheral compartment.  In the urine, up to 12% of the administered dose has been recovered during a dosing interval as unchanged pentamidine.</paragraph>
                        <paragraph>Tissue distribution was studied in mice given a single intraperitoneal injection of pentamidine at 10 mg/kg.  The concentration was highest in the kidneys followed by the liver.  In mice, pentamidine was excreted unchanged, primarily via the kidneys with some elimination in the feces.  The ratio of amounts excreted in the urine and feces (4:1) was constant over the period of study.</paragraph>
                        <paragraph>Tissue distribution has also been studied in normal and in renally impaired dogs (N = 3 each) given 13 mg/kg of pentamidine IV, in 2 doses separated by five weeks.  The concentration of pentamidine was highest in the liver followed by kidneys and lungs.  Pentamidine was concentrated in these organs approximately 70 to 1000 times that of the peak serum concentration.  Similar findings were reported in normal and in renally impaired dogs (N = 2 each) given 97.5 mg/kg of pentamidine IV, in 15 daily doses.  After repeated doses, the organs showed a further 3 to 7 fold accumulation while serum concentrations remained unchanged.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="72f1532a-da42-4d20-8172-a604d0eb2451"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Pentamidine isethionate for injection is indicated for the treatment of pneumonia due to <content styleCode="italics">Pneumocystis carinii.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="30dd286c-6e6c-4976-98a6-4526feda4c19"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Contraindicated in patients with a history of hypersensitivity to pentamidine isethionate.</paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="64fcaa68-49a0-45c8-a868-0c1ce34ea0c8"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes.  Severe hypotension may result after a single IM or IV dose and is more likely with rapid IV administration (see <content styleCode="bold">
                        <linkHtml href="#s7">PRECAUTIONS</linkHtml>
                     </content>).  The administration of the drug should, therefore, be limited to the patients in whom <content styleCode="italics">Pneumocystis carinii</content> has been demonstrated.  Patients should be closely monitored for the development of serious adverse reactions (see <content styleCode="bold">
                        <linkHtml href="#s7">PRECAUTIONS</linkHtml>
                     </content> and <content styleCode="bold">
                        <linkHtml href="#s10">ADVERSE REACTIONS</linkHtml>
                     </content>).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Extravasations have been reported which, in some instances, proceeded to ulceration, tissue necrosis and/or sloughing at the injection site.  While not common, surgical debridement and skin grafting has been necessary in some of these cases; long-term sequelae have been reported.  Prevention is the most effective means of limiting the severity of extravasation.  The intravenous needle or catheter must be properly positioned and closely observed throughout the period of pentamidine isethionate administration.  If extravasation occurs, the injection should be discontinued immediately and restarted in another vein.  Because there are no known local treatment measures which have proven to be useful, management of the extravasation should be symptomatic.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="c4162ea6-98ab-4a6a-910c-974c79219d34"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20190501"/>
               <component>
                  <section ID="s8">
                     <id root="13a7cad6-12f9-40c0-b6a3-04a2defc2aa3"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Pentamidine isethionate should be used with caution in patients with hypertension, hypotension, ventricular tachycardia, hypoglycemia, hyperglycemia, hypocalcemia, pancreatitis, leukopenia, thrombocytopenia, anemia, hepatic or renal dysfunction and Stevens-Johnson syndrome.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Patients may develop sudden, severe hypotension after a single dose of pentamidine isethionate, whether given IV or IM.  Therefore, patients receiving the drug should be lying down and the blood pressure should be monitored closely during administration of the drug and several times thereafter until the blood pressure is stable.  Equipment for emergency resuscitation should be readily available.  If pentamidine isethionate is administered IV, it should be infused over a period of 60 to 120 minutes.</content>
                        </paragraph>
                        <paragraph>Pentamidine isethionate-induced hypoglycemia has been associated with pancreatic islet cell necrosis and inappropriately high plasma insulin concentrations.  Hyperglycemia and diabetes mellitus, with or without preceding hypoglycemia, have also occurred, sometimes several months after therapy with pentamidine isethionate.  Therefore, blood glucose levels should be monitored daily during therapy with pentamidine isethionate, and several times thereafter.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="c781b6ba-59cf-4372-9743-32fed6234d46"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Renal and Hepatic Impairment
                     </title>
                     <text>
                        <paragraph>The efficacy or safety of alternative Pentamidine Isethionate dosing protocols have not been established for patients with impaired renal or hepatic function.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.1">
                     <id root="05bec4a3-8c0f-42f8-95b3-3572ab4180e5"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Laboratory Tests
                     </title>
                     <text>
                        <paragraph>The following tests should be carried out before, during and after therapy:</paragraph>
                        <list listType="ordered" styleCode="LittleAlpha">
                           <item>Daily blood urea nitrogen and serum creatinine determinations.</item>
                           <item>Daily blood glucose determinations.</item>
                           <item>Complete blood count and platelet count.</item>
                           <item>Liver function test, including serum bilirubin, alkaline phosphatase, AST (SGOT), and ALT (SGPT).</item>
                           <item>Serum calcium determinations.</item>
                           <item>Electrocardiograms.</item>
                        </list>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.2">
                     <id root="8c7dc88e-b741-4a4b-b3d4-0cad4913efb1"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>No drug interaction studies with Pentamidine Isethionate have been conducted.</paragraph>
                        <paragraph>Because the nephrotoxic effects may be additive, the concomitant or sequential use of pentamidine isethionate and other nephrotoxic drugs such as aminoglycosides, amphotericin B, cisplatin, foscarnet, or vancomycin should be closely monitored and avoided, if possible.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.3">
                     <id root="195a0ebf-743b-471f-a912-d624ae2d7984"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No studies have been conducted to evaluate the potential of pentamidine isethionate as a carcinogen, mutagen, or cause of impaired fertility.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.4">
                     <id root="ef1df278-ea32-4dcc-8f46-da6e401e0540"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Pregnancy-Pregnancy Category C</title>
                     <text>
                        <paragraph>Animal reproduction studies have not been conducted with pentamidine isethionate.  It is also not known whether pentamidine isethionate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Pentamidine isethionate should not be given to a pregnant woman unless the potential benefits are judged to outweigh the unknown risks.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.5">
                     <id root="290c1a2a-2471-4e9b-8b5b-6b1e9a6e1184"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether pentamidine isethionate is excreted in human milk.  Because of the potential for serious adverse reactions in nursing infants from pentamidine isethionate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  Because many drugs are excreted in human milk, pentamidine isethionate should not be given to a nursing mother unless the potential benefits are judged to outweigh the unknown risks.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s9.6">
                     <id root="717d3fe6-a829-4024-90c1-c52b6e88c307"/>
                     <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Intravenous and intramuscular pentamidine has been described as an effective treatment for <content styleCode="italics">Pneumocystis carinii</content> pneumonia (PCP) in immunocompromised pediatric patients beyond 4 months of age.  The efficacy and safety profiles in these pediatric patients were similar to those observed in adult patients (See <content styleCode="bold">
                              <linkHtml href="#s12">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#s11">OVERDOSAGE</linkHtml>)</content>.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="430d7dc8-8363-4c34-a113-ac7e0ae1a7d1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">CAUTION</content>: Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes.  Nephrotoxic events (increased creatinine, impaired renal function, azotemia, and renal failure) are common with the parenteral administration of pentamidine isethionate.  The administration of the drug should, therefore, be limited to the patients in whom <content styleCode="italics"> Pneumocystis carinii</content> has been demonstrated.</paragraph>
                  <paragraph>The most frequently reported spontaneous adverse events (1 to 30%) reported in clinical trials, regardless of their relation to pentamidine isethionate therapy were as follows (n=424):</paragraph>
                  <table width="50%">
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Cardiovascular:</paragraph>
                              <paragraph>   Hypotension</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">5.0%
									</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Gastrointestinal:</paragraph>
                              <paragraph>   Anorexia/Nausea</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">5.9%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hematologic:</paragraph>
                              <paragraph>   Anemia</paragraph>
                              <paragraph>   Leukopenia</paragraph>
                              <paragraph>   Thrombocytopenia</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">1.2%<br/>10.4%<br/>2.6%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hepatic:</paragraph>
                              <paragraph>   Elevated liver function tests</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">8.7%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Metabolic:</paragraph>
                              <paragraph>   Hypoglycemia</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">5.9%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Neurologic:</paragraph>
                              <paragraph>   Confusion/hallucinations</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">1.7%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Skin:</paragraph>
                              <paragraph>   Sterile abscess and/or necrosis,</paragraph>
                              <paragraph>   pain, or induration at the site of</paragraph>
                              <paragraph>   IM injection</paragraph>
                              <paragraph>   Rash</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">11.1%<br/>	3.3%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Special Senses:</paragraph>
                              <paragraph>   Bad taste</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">1.7%</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Urogenital:</paragraph>
                              <paragraph>   Azotemia</paragraph>
                              <paragraph>   Elevated serum creatinine</paragraph>
                              <paragraph>   Elevated blood urea nitrogen</paragraph>
                              <paragraph>   Impaired renal function</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="bottom" align="center">8.5%<br/>23.6%<br/>6.6%<br/>28.8%</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Adverse events with a frequency of less than 1% incidence were as follows (No causal relationship to treatment has been established for these adverse events): 
 </paragraph>
                  <table>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Body as a whole:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Allergic reaction (i.e. urticaria, itching, rash), anaphylaxis, arthralgia, chills, extrapulmonary pneumocystosis, headache, night sweats, and Stevens-Johnson syndrome.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Cardiovascular:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Abnormal ST segment of electrocardiogram, cardiac arrhythmias, cerebrovascular accident, hypertension, palpitations, phlebitis, syncope, tachycardia, vasodilatation, vasculitis and ventricular tachycardia.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Gastrointestinal:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Abdominal pain, diarrhea, dry mouth, dyspepsia, hematochezia, hypersalivation, melena, pancreatitis, splenomegaly, and vomiting.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hematological:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Defibrination, eosinophilia, neutropenia, pancytopenia, and prolonged clotting time.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hepatic:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hepatic dysfunction, hepatitis and hepatomegaly</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Metabolic:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Hyperglycemia, hyperkalemia, hypocalcemia, and hypomagnesemia.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Neurological:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Anxiety, confusion, depression, dizziness, drowsiness, emotional lability, hypesthesia, insomnia, memory loss, neuropathy, nervousness, neuralgia, paranoia, paresthesia, peripheral neuropathy, seizure, tremors, unsteady gait, and vertigo.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Respiratory system:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Asthma, bronchitis, bronchospasm, chest congestion, chest tightness, coryza, cyanosis, eosinophilic or interstitial pneumonitis, gagging, hemoptysis, hyperventilation, laryngitis, laryngospasm, non-specific lung disorder, nasal congestion, pleuritis, pneumothorax, rales, rhinitis, shortness of breath, and tachypnea.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Skin:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Desquamation, dry and breaking hair, dry skin, erythema, dermatitis, pruritus, rash, and urticaria.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Special senses:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Blepharitis, blurred vision, conjunctivitis, contact lens discomfort, eye pain or discomfort, loss of hearing, loss of taste, and loss of smell.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Urogenital:</paragraph>
                           </td>
                           <td styleCode="Lrule Rrule Toprule Botrule" valign="top">
                              <paragraph>Flank pain, hematuria, incontinence, nephritis, renal dysfunction and renal failure.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>From post-marketing clinical experience with pentamidine isethionate, the following adverse events have been reported: cough, diabetes mellitus/ketoacidosis, dyspnea, infiltration (extravasation–see <content styleCode="bold">
                        <linkHtml href="#s6">WARNINGS</linkHtml>
                     </content>), and torsades de pointes.</paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="e4784649-9be2-47a3-948f-48064c16f4ee"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>A 17 month old infant inadvertently received 1600 mg of intravenous pentamidine isethionate which was followed by renal and hepatic function impairment, hypotension and cardiopulmonary arrest.  Treatment included cardiopulmonary resuscitation, epinephrine, atropine and intubation.  In addition, a four hour course of charcoal hemoperfusion was accompanied by reduction of pentamidine serum concentration and stabilization of the patient’s condition.  The patient recovered from these adverse events, but later died due to an unknown cause. <sup>1</sup>
                  </paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s12">
               <id root="693f05fd-b051-4428-9b25-292586c7db20"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">CAUTION: DO NOT USE SODIUM CHLORIDE INJECTION, USP FOR INITIAL RECONSTITUTION BECAUSE PRECIPITATION WILL OCCUR.</content>  Pentamidine isethionate should be administered IM or IV only.  The recommended regimen for adults and pediatric patients beyond 4 months of age is 4 mg/kg once a day for 14 to 21 days.  Therapy for longer than 21 days with pentamidine isethionate has also been used but may be associated with increased toxicity.</paragraph>
               </text>
               <effectiveTime value="20190501"/>
               <component>
                  <section ID="s12.1">
                     <id root="5e0d2de8-882f-4aec-afc6-9d9ff6f99343"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Intramuscular Injection</title>
                     <text>
                        <paragraph>The contents of one vial (300 mg) should be dissolved in 3 mL of Sterile Water for Injection, USP at 22° - 30°C (72° - 86°F).  The calculated daily dose should then be withdrawn and administered by deep IM injection.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.2">
                     <id root="f0000b15-ee85-4056-895b-d65bce9e156f"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Intravenous Injection</title>
                     <text>
                        <paragraph>The contents of one vial (300 mg) should first be dissolved in 3 to 5 mL of Sterile Water for Injection, USP, or 5% Dextrose Injection, USP at 22°- 30°C (72° - 86°F).  The calculated dose of pentamidine isethionate should then be withdrawn and diluted further in 50 to 250 mL of 5% Dextrose Injection, USP.</paragraph>
                        <paragraph>
                           <content styleCode="bold">The diluted IV solutions containing pentamidine isethionate should be infused over a period of 60 to 120 minutes.</content>
                        </paragraph>
                        <paragraph>Aseptic technique should be employed in preparation of all solutions.  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
               <component>
                  <section ID="s12.3">
                     <id root="f2c03d71-2279-4644-8c39-ed1ef7a52582"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>Stability</title>
                     <text>
                        <paragraph>After reconstitution with sterile water, the Pentam solution is stable for 48 hours in the original vial at room temperature if protected from light.  To avoid crystallization, store at 22° - 30°C (72° - 86°F).  Intravenous infusion solutions of pentamidine isethionate at 1 mg/mL and 2.5 mg/mL prepared in 5% Dextrose Injection, USP are stable at room temperature for up to 24 hours.</paragraph>
                        <paragraph>Intravenous (IV) solutions of pentamidine isethionate have been shown to be incompatible with fluconazole and foscarnet sodium.  IV solutions of pentamidine isethionate have been shown to be compatible with IV solutions of zidovudine (AZT) and diltiazem hydrochloride.</paragraph>
                     </text>
                     <effectiveTime value="20190501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="9a50e10c-0b5c-42c3-bcb0-0de07a400d2d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <table>
                     <tbody>
                        <tr>
                           <td valign="top" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>
                                 <content styleCode="bold">NDC</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">No.</content>
                              </paragraph>
                           </td>
                           <td valign="top" styleCode="Botrule Lrule Rrule Toprule"/>
                        </tr>
                        <tr>
                           <td valign="top" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>13925-515-10 </paragraph>
                           </td>
                           <td valign="top" styleCode="Botrule Lrule Rrule Toprule">
                              <paragraph>Pentamidine Isethionate for injection 300 mg, lyophilized product in single-dose vials, packages of 10.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store dry product at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.</paragraph>
                  <paragraph>Preservative Free.  Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section ID="s14">
               <id root="f7f45552-214b-4d95-b35a-6365a2410afb"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>REFERENCE</title>
               <text>
                  <list listType="ordered">
                     <item>Watts RG; Conte JE, Jr.; Zurlinden E; Waldo FB: Effect of charcoal hemoperfusion on clearance of pentamidine isethionate after accidental overdose. J Toxicol Clin Toxicol 1997;35:89-92.</item>
                  </list>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ebb5e405-0c7e-4d34-9ca0-cd52c81d15c8"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured for:<br/>
                     <content styleCode="bold">Seton Pharma, LLC</content>
                     <br/>Manasquan, NJ 08736</paragraph>
                  <paragraph>Revised: January 2014</paragraph>
               </text>
               <effectiveTime value="20190501"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9923e320-66a9-4f46-bbe2-0a6fddc51730"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 13925-515-10</paragraph>
                  <paragraph>
                     <content styleCode="bold"> Pentamidine Isethionate for Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">300 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Lyophilized</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">For IM or IV Use</content>
                  </paragraph>
                  <paragraph>Single-Dose Vial</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="mm02"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Single Dose Vial Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 13925-515-10</paragraph>
                  <paragraph>Pentamidine Isethionate for Injection</paragraph>
                  <paragraph>300 mg</paragraph>
                  <paragraph>Lyophilized</paragraph>
                  <paragraph>For Intramuscular or Intravenous Use</paragraph>
                  <paragraph>10 Single-Dose Vial</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L333592bb-5f3d-417b-a8fb-fa2b00605c1c"/>
                  </paragraph>
               </text>
               <effectiveTime value="20190501"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Vial Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="vial-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L333592bb-5f3d-417b-a8fb-fa2b00605c1c">
                     <text>Carton Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-label.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>